🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We wish you #MerryChristmas and a Happy #NewYear2025

Esther Riambau es una de las investigadoras contra el cáncer que apoyamos. Con motivo del #DíaInternacionaldelaMujerylaNiñaenlaciencia, te acercaremos al trabajo de mujeres que hoy están cambiando el futuro del cáncer con investigación. #Investigandoencáncer

#DíaMujeryNiñaenlaCiencia Te presentamos 12 investigadoras que han perseguido su sueño hasta conseguir que con su trabajo se consiga superar el 70% de supervivencia en cáncer. ¡Gracias a todas ellas! Descúbrelas 👇 view.genially.com/67a07a9051e107… Colabora Johnson&Johnson

We are enjoying #MWC25 & #4YFN25! As a biopharmaceutical company focused on #PrecisionOncology, we want to show our innovative therapy ONR-001 for aggressive solid and liquid tumors that don't respond to current treatments. 📍 Hall 8.1 - Stand 8.1C23.1A - Fira Barcelona

La III edición de #UnDíaConUnaMujerBiotech continúa. 🚀 Celia Mata González estudiante de Granada Universidad Granada comparte una jornada inspiradora con Esther Riambau Gascó, CEO en Oniria Therapeutics Mujeres que impulsan el cambio #biotech. 🌿 #MujeresBiotech #SomosBiotecnología Mercados Biotec

We invite you to the poster presentation “First-in-class TET2 small drug allosteric activator to fight #CancerPersistence” by our Scientist David Aguilar at the European Association for Cancer Research Conference in Lyon. 📄 N. 53 🗓️ 18 March 🕕 6:15 pm bit.ly/3FrP7Vj

Ready to start the EACR Conference: Persister Cells: from Bacteria to Cancer in Lyon!!!!

The EACR Conference “Persister Cells: from Bacteria to Cancer” is taking place in Lyon. Thank you to everyone who attended our presentation “First-in-class TET2 small drug allosteric activator to fight #CancerPersistence”, especially Yaara Oren, chair of the Scientific Committee